WZH-17-002
WZH-17-002 is a WZH-15-125-based ALK PROTAC degrader with a DC50 of 25 nM. WZH-17-002 enhances activities against Lorlatinib (HY-12215) -resistant ALK compound mutations. WZH-17-002 significantly reduces drug resistance in ALK-fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196 M xenograft mice model[1]. Pink: ALK ligand (HY-174314) ; Blue: CRBN ligase ligand (HY-14658) ; Black: linker (HY-174316)
Product Specifications
UNSPSC
12352005
Target
Akt; Anaplastic lymphoma kinase (ALK) ; ERK; PROTACs
Related Pathways
MAPK/ERK Pathway; PI3K/Akt/mTOR; PROTAC; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(N(CC1)CCN1C(CC2)CCN2C(C(CC)=C3)=CC(OC)=C3NC(N=C4NC5=CC=C6OCCOC6=C5N(S(C)(=O)=O)C)=NC=C4Br)CNC7=C8C(N(C9CCC(NC9=O)=O)C(C8=CC=C7)=O)=O
Molecular Formula
C47H54BrN11O10S
Molecular Weight
1044.97
References & Citations
[1]Gao F, et al. Discovery of an ALK degrader for lorlatinib-resistant compound mutations. Eur J Med Chem. 2025 Jun 2;296:117835.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human GRIK5 shRNA (UAS) - Lentiviral human GRIK5 shRNA (UAS) (25)